OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners

Core Insights - OKYO Pharma Limited has transitioned its At-The-Market (ATM) equity offering facility to Leerink Partners LLC, enhancing its ability to access capital markets efficiently [1][2] - The new partnership with Leerink Partners is expected to provide financial flexibility to support ongoing clinical development, particularly for its lead candidate urcosimod for neuropathic corneal pain [2] Company Overview - OKYO Pharma is a clinical-stage biopharmaceutical company focused on developing therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, with shares listed on the Nasdaq Capital Market [4] - The company recently completed a successful Phase 2 trial of urcosimod and plans to initiate a Phase 2b/3 multiple-dose study involving approximately 150 subjects in the first half of the year [4]